| Master Investor Magazine
|
Infection prevention and contamination control specialist Tristel (LON:TSTL) has seen its share price increase by 1.53% to 298p (as of 13:35 BST) as turnover rose by 18%, driven by strong overseas growth. Profits before taxation before taxation for the period were up by 18%.
CEO Paul Swinney commented: “We made solid progress during the year. Top-line growth was driven by our overseas operations and this trend should continue with the acquisition of four of our main European distributors during the year and shortly after the year-end. We were also pleased with 9% sales growth in the United Kingdom which was higher than in recent years. Our direct involvement in the French ultrasound market has been very timely with the publication of new guidelines in the early Summer. We have built a seven-strong salesforce to take advantage of buoyant demand conditions. Our progress in developing both sales and the sales team in China and Hong Kong is encouraging, focussing our efforts in the near term on the private hospital sector whilst we wait for new ultrasound disinfection guidelines to be published which will impact the public sector.
“We are advancing our De Novo submission for Duo to the USA Food and Drug Administration and are awaiting feedback to our most recent pre-submission request to the agency. We expect to receive this before the end of 2019“.